Lincoln Pharmaceuticals reported a solid H1 FY2027 performance, with net profit rising 20.5% to Rs 57.50 crore and income growing 18.4% to Rs 402.43 crore. The company maintains a net-debt-free status and is scaling its global footprint, targeting 90 countries with a revenue goal of Rs 1,000 crore within three years.
Lincoln Pharmaceuticals Posts Strong H1 Growth
Lincoln Pharmaceuticals reported a net profit of Rs 57.50 crore for H1 FY2027, up 20.52% YoY, with total income reaching Rs 402.43 crore.
Reader Takeaway: Strong double-digit profitability and a debt-free balance sheet support expansion, though global market execution remains a critical monitor.
What just happened
The company released its financial results for the quarter and half-year ended September 30, 2026. For H1 FY2027, consolidated net profit rose to Rs 57.50 crore from Rs 47.71 crore in the previous year. Revenue grew by 18.39% to Rs 402.43 crore, while EBITDA improved by 18.37% to Rs 84.92 crore. In the standalone Q2 FY27 quarter, the company recorded a profit of Rs 20.84 crore on revenues of Rs 200.88 crore.
Why this matters
Lincoln Pharmaceuticals is signaling a phase of aggressive growth. The company is now debt-free and has successfully commissioned a new API facility at its Khatraj plant. By shifting its energy needs to near 100% renewable sources, the company is effectively managing overhead costs, which supports its long-term margin goals.
Management Guidance
The company has set a firm revenue target of Rs 1,000 crore to be achieved over the next three years, implying a consistent annual growth rate of 15-18%. Management intends to leverage its presence in cardiac, diabetic, and ENT therapeutic segments to drive this expansion.
Risks to watch
Investors should closely watch the execution of the international expansion strategy. The company aims to move from 60 countries to 90 countries in the next 2-3 years. Scaling domestic divisions and sustaining current margins during this transition will be essential to meeting the long-term revenue targets.
What to track next
Watch for updates on the contribution of the four newly introduced domestic divisions and the utilization levels of the new API manufacturing unit at Khatraj in upcoming quarterly filings.